Nutritional Advice El Mondo
Objectives:
National Institute for Health and Care Excellence (NICE) endorsed clinical frailty scale (CFS) to help with decision-making. However, this recommendation lacks an evidence basis and is controversial. Therefore, this review article has been conducted.
Does an increase in clinical frailty scale (CFS) increase mortality risk among COVID-19 patients?
Study design:
This review article included 7 studies with a total of 3,817 COVID-19 patients.
Mean age was 80.3 [SD = 8.2] and 53% [95% CI = 48% to 58%] were males.
Results and conclusions:
The investigators found pooled prevalence for clinical frailty scale 1-3 was 34% [95% CI = 32% to 36%], clinical frailty scale 4-6 was 42% [95% CI = 40% to 45%] and clinical frailty scale 7-9 was 23% [95% CI = 21% to 25%].
The investigators found each 1-point increase in clinical frailty scale was associated with 12% increase in mortality [OR = 1.12, 95% CI = 1.04 to 1.20, p = 0.003, I2 = 77.3%]. However, the funnel-plot analysis was asymmetrical, therefore, the trim-and-fill analysis was carried out; trim-and-fill analysis by the imputation of two studies on the left side resulted in OR of 1.10 [95% CI = 1.03 to 1.19].
The investigators found the dose-response relationship was linear [p non-linearity = 0.116].
The investigators concluded that increase in clinical frailty scale (CFS) is associated with increase in mortality among COVID-19 patients in a linear fashion.
Original title:
Clinical frailty scale and mortality in COVID-19: A systematic review and dose-response meta-analysis by Pranata R, Henrina J, […], Setiati S.
Link:
https://pubmed.ncbi.nlm.nih.gov/33352430/
Additional information of El Mondo:
Find more information/studies on coronavirus right here.